By Colin Kellaher


Bayer AG on Monday said it has filed for U.S. and European expanded approval of its cancer drug Aliqopa in combination with rituximab, a drug used to treat certain types of cancer and rheumatoid arthritis.

The Leverkusen, Germany, chemical and pharmaceutical company said it is seeking U.S. Food and Drug Administration approval of the combination in relapsed indolent B-cell non-Hodgkin's lymphoma.

The company said it also has filed for European Medicines Agency approval for the treatment of relapsed marginal zone lymphoma, a subtype of indolent B-cell non-Hodgkin's lymphoma.

Bayer in April said a Phase III study showed a significant progression-free survival benefit for the combination in patients with relapsed indolent non-Hodgkin's lymphoma.

The FDA in 2017 approved Aliqopa for adults with relapsed follicular lymphoma who have received at least two prior systemic therapies.


Write to Colin Kellaher at


(END) Dow Jones Newswires

June 21, 2021 11:26 ET (15:26 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Bayer (XE:BAYN)
Historical Stock Chart
From Aug 2021 to Sep 2021 Click Here for more Bayer Charts.
Bayer (XE:BAYN)
Historical Stock Chart
From Sep 2020 to Sep 2021 Click Here for more Bayer Charts.